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Inflammation characterizes the course of acute and chronic diseases and is largely responsible for the metabolic and behavioral
changes occurring during the clinical journey of patients. Robust data indicate that, during cancer, functional modifications within
brain areas regulating energy homeostasis contribute to the onset of anorexia, reduced food intake, and increased catabolism of
muscle mass and adipose tissue. In particular, functional changes are associated with increased hypothalamic concentration of
proinflammatory cytokines, which suggests that neuroinflammationmay represent the adaptive response of the brain to peripheral
challenges, including tumor growth. Within this conceptual framework, the vagus nerve appears to be involved in conveying alert
signals to the hypothalamus, whereas hypothalamic serotonin appears to contribute to triggering catabolic signals.
1. Introduction
Metabolic changes due to tumour growth profoundly impact
nutritional status [1]. Anorexia and reduced food intake are
frequently the presenting symptoms of several types of cancer
[1, 2]. Although anorexia and reduced food intake largely
contribute to weight loss of cancer patients, wasting cannot
be accounted for by inadequate eating only. Indeed, cancer-
induced derangement of protein, carbohydrate, and lipid
metabolism magnifies the impact of anorexia on nutritional
status and also reduces the efficacy of nutritional interven-
tions [2].
Tumor-associated changes of energy and macronutrient
metabolism, together with behavioral changes (i.e., anorexia
and reduced food intake), negatively influence patients’
quality of life and increase their morbidity and mortality
[3]. Inflammation plays a major role in the pathogenesis
of metabolic and behavioral abnormalities during disease.
Consequently, inflammatory markers are frequently used as
predictors not only of metabolic abnormalities but of clinical
outcome as well. As an example, high circulating levels of
C-reactive protein (CRP) are frequently observed in cancer
patients with cachexia. Thus, CRP levels, in combination
with reduced food intake and weight loss, could be used as
a clinical marker of cancer cachexia. Moreover, CRP might
be directly involved in cancer-related wasting since it has
been shown to exacerbate tissue injury of ischemic necrosis
in heart attack and stroke [4]. Therefore, a potential role
for CRP in inflammatory conditions such as cancer could
be speculated, in which increased CRP production leads to
binding of CRP to exposed ligands in damaged cells, thereby
increasing tissue injury [5]. Systemic inflammation is also
correlated with increased proteasome-mediated proteolysis
in skeletal muscle of cancer patients [6].
Cancer anorexia also appears to be significantly influ-
enced by increased inflammatory status, as demonstrated by
increased brain levels of proinflammatory cytokines such as
interleukin-1 (IL-1) and tumor necrosis factor-𝛼 (TNF𝛼) in
experimentalmodels of cancer anorexia [7–11]. In fact, block-
ade of circulating TNF or inhibition of intrahypothalamic
interleukin-1 receptors enhances food intake in animal mod-
els of cancer anorexia [12, 13]. Proinflammatory cytokines
alter brain neurochemistry by enhancing the release of
neurotransmitters able to influence neuronal anorexigenic
pathways such as serotonin [14]. Further supporting the role
of increased inflammatory response in mediating the onset
of anorexia, Jatoi et al. showed in a prospective, controlled,
randomized trial that the percentage of cancer patients
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Figure 1: The growing tumor is sensed by the brain via neural, humoral, and inflammatory input. These signals activate the behavioural and
metabolic response to stress by activatingmicroglia cells, although it cannot be excluded that signals from peripheral tissues directly influence
the activity of hypothalamic neurons, at least in the initial phase of the response to stress. Microglia activation triggers and perpetuates
neuroinflammation, which is characterized by the release of inflammatory mediators within the hypothalamic areas. In the arcuate nucleus,
inflammatory response hyperactivates catabolic neurons, that is, melanocortin (MC) neurons, which in turn contribute to the inhibition of
prophagic neurons, that is, neuropeptide Y (NPY) neurons. Disruption of the physiological balance between the activity of MC and NPY
neurons yields to the behavioural and metabolic consequences of cachexia. Experimental data also suggest that neuroinflammation may
contribute to tumour growth and aggressiveness by modulating the peripheral immune response through autonomic output.
with appetite improvement was similar following eicosapen-
taenoic acid (EPA) supplementation or megestrol acetate
intake, a potent appetite enhancer [15]. EPA is an omega-
3 fatty acid whose biological effects include the modulation
of inflammatory response. By competing with omega-6 fatty
acids, EPA is degraded by cellular lipoxygenase and cyclooxy-
genase. However, the prostaglandins and leukotrienes deriv-
ing from the degradation of EPA exert less proinflamma-
tory activities when compared to the prostaglandins and
leukotrienes deriving from the degradation of omega-6 fatty
acids. Therefore, reduced production of omega-6 fatty acid-
derivedmediators of inflammation through supplementation
of pharmacological doses of omega-3 fatty acids is now con-
sidered to play a contributory role in reducing inflammation
and promoting preservation of nutritional status in cancer
patients [16].
2. Interaction between Neuroinflammation
and Neurotransmission
During cancer, the physiological functioning of the brain
areas controlling energy homeostasis is disrupted. Consistent
evidence indicates that increased hypothalamic expression
and release of mediators of inflammation play a large role
in this event (Figure 1). Proinflammatory cytokines such
as IL-1 and TNF𝛼 have been recognized for many years
as principal actors in the pathogenesis of anorexia and
cachexia [17]. Hypothalamic IL-1 mRNA expression and IL-
1 levels are significantly increased in the cerebrospinal fluid
of anorexic tumor-bearing rats and inversely correlate with
energy intake [7, 18]. The causative role of brain IL-1 in
cancer anorexia and cachexia is supported by data showing
that anorexia ameliorates after intrahypothalamic injection of
the IL-1 receptor antagonist [19]. Intraperitoneal injection of
recombinant human soluble TNF𝛼 receptor in experimental
models improves anorexia thus confirming the role of TNF𝛼
in the negative modulation of appetite [12]. Finally, megestrol
acetate, a potent orexigenic drug largely used in cancer
patients, improves food intake by reducing the expression of
IL-1 by mononuclear cells and by increasing hypothalamic
concentrations of the prophagic mediator neuropeptide Y
(NPY), which confirms the significant role of IL-1 in medi-
ating cancer-associated anorexia in humans [20, 21].
Proinflammatory cytokines appear to exert their effects
through their influence on the physiological hypothalamic
pathway promoting catabolism, that is, the melanocortin
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system. Intracerebroventricular injection of IL-1 increases
the frequency of signaling of melanocortin neurons in the
arcuate nucleus of hypothalamus which express the type 1 IL-
1 receptor. In addition, IL-1 stimulates the release of 𝛼-MSH
[22]. Also, the classical neurotransmitter serotonin appears to
be involved (Figure 1).
Serotonin contributes to energy balance by triggering
satiety through its effects in the hypothalamus [23, 24].
Increased hypothalamic serotonin levels have been associated
with the onset of cancer anorexia in experimental in vivo
models and increased expression of serotonin receptors (5-
HTRs). The link between serotonergic neurotransmission
and disease-related anorexia is confirmed by the restoration
of energy intake after tumor resection and normalization of
hypothalamic serotonin concentrations and receptor expres-
sion [25, 26]. Intrahypothalamic injection of the serotonin
antagonist mianserin ameliorates energy intake in experi-
mental models of anorexia [13].The synthesis of the hormone
melatonin is determined by its precursor serotonin. Mela-
tonin modulates the activity of the hypothalamic suprachias-
matic nucleus and alters biological rhythms. Disrupted mela-
tonin synthesis and secretion in patients with cachexia and in
wasted animals may contribute to serotonin accumulation in
the hypothalamus [27, 28]. Serotonin plays a role in disease-
associated anorexia, as confirmed by increased plasma and
cerebrospinal fluid levels of the amino acid tryptophan, the
precursor of serotonin, in anorexic and cachectic cancer
patients [29]. Catabolic effects may be the consequence of
the brain accumulation of tryptophan during the disease [30].
Brain tryptophan is also crucial in determining the release of
kynurenine and its derivatives, molecules able to modulate
immune functions [30]. Kynurenine represents the most
important pathway, because tryptophan is mostly degraded
via this pathway, producing 3-hydroxykynurenine and 3-
hydroxyanthranilic acid, which represent acid free radical
generators. The rate of tryptophan degradation through the
kynurenine pathway is mediated directly by inflammation.
In this light, the accumulation of brain tryptophan cou-
pled with increased release of proinflammatory cytokines
may maintain tryptophan metabolism toward increased
free radicals production, determining enhanced oxidative
stress. In experimental models of cancer-associated anorexia,
increased concentrations of markers of oxidative stress have
been measured in hypothalamic regions involved in the
control of energy homeostasis [31].
As previously mentioned, melatonin biosynthetic path-
way might be involved in the pathogenesis of anorexia.
Melatonin exerts antioxidant function, and since the brain
is largely composed of unsaturated fatty acids, preferential
targets of reactive oxygen species, it could be speculated
that melatonin supplementation may limit brain oxidation-
induced inflammation and thus ameliorate anorexia and
cachexia. However, Del Fabbro et al. have recently reported
that oral melatonin 20mg at night did not improve appetite,
weight, or quality of life compared with placebo [32]. How-
ever, since the trial involved, among others, patients with
gastrointestinal cancer, a role for the mechanical impact
of tumor burden on the lack of clinical effects cannot be
excluded.
3. The Melanocortin System and Its Role
during Inflammation
Melanocortin system mediates the anorectic effects of sero-
tonin, as demonstrated by the activation of the central
melanocortin pathway after the administration of fenflu-
ramine, a serotonin reuptake inhibitor [33]. Studies have
focused on 2 subtypes of serotonin receptors, the 5-HT2cR
and the 5-HT1bR which are located within the arcuate
nucleus of the hypothalamus. Anorexigenic neurons express
5-HT2cRs, whereas orexigenic NPY neurons express 5-
HT1bRs. Agonists activate these receptors thus hyperpo-
larizing the NPY neurons while dramatically reducing the
inhibitory postsynaptic potentials in melanocortin neurons
[34]. An improvement in glucose tolerance and a decrease in
plasma insulin levels were consequent to the administration
of doses of 5-HT2cR agonists in experimental models of
obesity via melanocortin-4 receptor signaling pathways [35].
Serotonin, IL-1, and TNF𝛼 are able to influence the activity of
the central melanocortin system. In fact, peripheral infusion
of IL-1 causes anorexia by increasing brain tryptophan levels
and serotonin synthesis [36]. TNF𝛼 and IL-1 are able to
regulate neuronal serotonin transporter [37]. Experimental
data suggest that catabolic states are associatedwith increased
hypothalamic expression of IL-1 together with enhanced
release of serotonin.The function of themelanocortin system
is conditioned by the interaction between serotonin and
IL-1 within the arcuate nucleus. The consequences are the
inhibition of NPY neuronal activity and the stopping of
the inhibition of melanocortin neurons. These effects alter
the melanocortin system by enhancing the release of 𝛼-
MSH, an endogenous melanocortin receptor type 4 (MC4R)
agonist, and suppressing the release of agouti-related pep-
tide (AgRP), an endogenous MC4R antagonist. Interest-
ingly, binding of 𝛼-MSH on MC1R reduces TNF𝛼 secretion
by macrophages, therefore determining anti-inflammatory
effects [38, 39].
The activation of themelanocortin system during periph-
eral acute stress is likely related to the direct sensing by
hypothalamic cells of humoral or nervous triggers. How-
ever, during chronic stress, the role of neuroinflammation,
and particularly of brain microglia, is key (Figure 1). The
most important immune effector cells of the brain are
microglia, the tissue macrophages of the brain, and they are
involved in the onset, maintenance, relapse, and progression
of brain inflammation. Under healthy conditions, microglia
is characterized by a ramified morphology, which is used
to continuously scan the environment. Upon any homeo-
static disturbance, microglia rapidly change their phenotype
and contribute to processes including inflammation, tissue
remodeling, and neurogenesis. During activation, microglia
releases neurotrophic factors, as well as neurotoxic factors
and proinflammatory cytokines. Host defense is dependent
on microglial activation, although detrimental effects have
been also reported. However, robust and consistent evidence
shows that microglia stimulates myelin repair, removal of
toxic proteins, and prevention of neurodegeneration [40].
Recent data show that functional phenotypes ofmicroglia dif-
fer according to the diverse brain regions and to the different
4 Mediators of Inflammation
types of stress (i.e., neuroinflammation, neurogenesis, brain
tumour homeostasis, and aging) [41].
4. From Neuroinflammation to Systemic
Inflammation
Consistent evidence supports the concept that inflammation
drives a multifactorial central and peripheral network of
signaling pathways involved not only in the pathogenesis of
cancer cachexia, but in tumor development and progression
as well. In addition, inflammatory response is associated
with increased circulating levels of specific cytokines, such
as IL-1, IL-6, IFN𝛾, TNF𝛼 [42], and acute-phase proteins
that lead to hypermetabolism and weight loss in patients
with anorexia and cachexia [43]. Also, in advanced stages
of cancer, IL-1𝛽 is strongly associated with loss of appetite,
weight loss, sarcopenia, and general weakness [44]. Despite
this robust evidence, it should be also acknowledged that
Kayacan et al. did find increased concentrations of TNF𝛼
and IL-6 in patients with lung cancer, but they could
not observe any significant difference between cachectic
and noncachectic patients [45]. This highlights the impor-
tance of considering the circadian rhythm of cytokine
production and release when measuring their circulating
levels.
The mechanistic interaction between neuroinflamma-
tion, systemic inflammation, and tumor development has not
yet been completely clarified. Evidences for a causal relation-
ship between neuroinflammation and systemic inflammation
and features of cachexia are increasing [46]. In models of
anorexia and cachexia, administration of proinflammatory
cytokines induced acute-phase protein response, anorexia,
weight loss, protein and adipose tissue catabolism, and
higher concentration of cortisol and glucagon, as well as
decreased insulin resistance and a positive modulation of
energy homeostasis [47]. In addition, high IL-6 levels corre-
lated with cachexia phenotype, while treatment with mon-
oclonal antibody to IL-6 reversed this picture [48]. When
the specific role of neuroinflammation in the development
and progression of cancer is considered (Figure 1), results
obtained show that the sympathetic nervous system modu-
lates the antitumor immune defense response. In fact, chemi-
cally sympathectomized tumor-bearing rats had significantly
increased neutrophil-to-lymphocyte ratio, an indicator of
disease progression, althoughno significant changes in tumor
growth and survival were observed [49]. Also, Magnon et
al. found that the formation of autonomic nerve fibers in
the prostate gland regulates prostate cancer development and
dissemination in mouse models. Moreover, a retrospective
blinded analysis of prostate adenocarcinoma specimens from
43 patients revealed that the densities of sympathetic and
parasympathetic nerve fibers in tumor and surrounding
normal tissue, respectively, were associated with poor clinical
outcomes [50]. Whether increased tumor innervation by
autonomic nervous system could be regulated by increased
brain inflammatory response remains to be ascertained.
However, microglial activation has been demonstrated to
contribute to the endocrine dysregulation and the elevated
sympathetic nerve activity reported in streptozotocin-treated
rats [51].
5. Brain and Muscle-Adipose Tissue Axis
Robust data indicate that the control of energy intake and
expenditure is largely mediated by the hypothalamus, and
centrally produced proinflammatory cytokines participate in
activating the molecular modifications inducing the devel-
opment of cancer-associated anorexia and cachexia [46].
Moreover, experimental models of wasting showed that
muscle catabolism during disease is activated by hypothala-
mic stimuli and cytokines may enhance the activity of the
hypothalamic melanocortin system promoting muscle and
adipose wasting [46].
The interaction between inflammatory mediators and
the central nervous system may occur at the peripheral
levels and may play a relevant role in triggering the host
inflammatory response. This inflammatory response, when
constantly present, may lead to the development of cachexia.
At peripheral levels, tumour growth could be sensed by the
vagus nerve, possibly by sensing the paracrine release of
proinflammatory cytokines [52]. This information is con-
veyed to brainstem regions and finally to the hypothalamus,
activating the melanocortin system through specific neural
intermediates and receptors [53]. The melanocortin system,
when activated, enhances the release of cytokines to reduce
food intake and promote muscle catabolism. Consequently,
inhibition of the brain inflammatory response that is induced
by cytokines may result in better clinical outcome than
systemic immune suppression. In this light, exploration of
the possible pathogenic and clinical roles of fatty acid-
derived modulators of inflammation may yield relevant
results.
As previously mentioned, EPA supplementation con-
tributes to anticachexia therapy by reducing inflammatory
response. Docosahexaenoic acid (DHA) is the major brain
omega-3 fatty acid and has been shown to be involved in the
biosynthesis of potent anti-inflammatory and proresolving
mediators by macrophages, maresins [54]. Although their
biological function has been investigated in experimen-
tal models of acute inflammation, a possible role during
clinical conditions characterized by mild to moderate, yet
chronic, inflammatory response, including cancer, cannot be
excluded. Greater relevance for the pathogenic link between
neuroinflammation and cachexia appears to be exerted by
neuroprotectins.
Similarly to maresins, DHA is the precursor of neu-
roprotectins as well [55]. Consistent evidence showed that
neuroprotectins attenuate brain damage following ischemia
and restore nerve integrity and function after experimental
surgery. Also, neuroprotectin D1 has been shown to induce
homeostatic regulation following proteotoxic stress induced
by misfolding proteins [56]. Such type of stress appears more
similar to that induced by a growing tumour and therefore
suggests that neuroprotectins could be a relevant therapeutic
target to specifically inhibit the brain contributory role to
cachexia of cancer.
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6. Conclusion
During the last few years, our knowledge of the mechanisms
regulating neural inflammation has been largely improved.
However, the impact on clinical practice of these advance-
ments in the pathophysiology of neuroinflammation and its
link with systemic inflammation is still lacking. This may
be determined by the heterogeneity of the symptoms char-
acterizing anorexia and cachexia in human conditions. It is
extremely likely that the different clinical conditions induced
by inflammation are determined by the polymorphisms of
different genetic profile [57], which in turn regulates the
neurochemical/metabolic response to similar challenges. In
this light, it appears mandatory to focus our research on the
identification of polymorphisms of key genes, regulating the
expression of inflammatory markers and possibly serotonin.
This approach will allow the use of preventative or early
anticatabolic therapies.
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